{
  "id": "5b407668-9dd2-4be1-bbe3-be82f8cecefe",
  "title": "Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline",
  "link": "https://seekingalpha.com/news/4459199-vistagen-targets-transformative-sad-drug-approval-with-top-line-palisademinus-3-data-in-q4?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Tue, 17 Jun 2025 18:50:29 -0400",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "vtgn"
  ],
  "byline": "",
  "length": 0,
  "excerpt": "",
  "siteName": "",
  "favicon": "",
  "text": "",
  "image": "",
  "html": "",
  "readingTime": "Less than 1 min",
  "publishedTime": null,
  "modifiedTime": null
}
